» Articles » PMID: 11342439

Proteolysis of the Urokinase-type Plasminogen Activator Receptor by Metalloproteinase-12: Implication for Angiogenesis in Fibrin Matrices

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 2001 May 9
PMID 11342439
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Pericellular proteolysis plays an important role in cell migration and the formation of new capillary structures. The plasminogen activator/plasmin and matrix degrading metalloproteinase (MMP) cascades act together in the remodeling of matrix and cell-matrix contacts. Previously we have shown that the formation of capillary structures by human foreskin microvascular endothelial cells (hMVECs) in a 3-dimensional fibrin matrix requires a functional urokinase-type plasminogen activator receptor (u-PAR). Here we report on the unexpected finding that inhibition of hMVEC-derived MMP activity by BB94 (batimastat) increased the outgrowth of capillary structures in a fibrin matrix. BB94 prevented the release of the u-PA binding domain D1 of u-PAR and thereby increased the number of functional u-PARs on hMVECs without affecting the u-PAR messenger RNA levels. Comparison of various types of protease inhibitors pointed to the prime involvement of MMP activity. Using recombinant MMPs it was shown that MMP-12 activity was able to release the D1 domain of cellularly expressed u-PAR. In addition, the expression of MMP-12 in control and basic fibroblast growth factor/tumor necrosis factor-alpha-stimulated hMVECs was shown by reverse transcriptase-polymerase chain reaction, suggesting that endothelial cell-derived MMP-12 may be involved in angiogenesis-related u-PAR shedding. This new mechanism of u-PAR cleavage provides new insights into the mutual interactions between the MMP and u-PA/plasmin systems. Moreover, it may be helpful in the interpretation of recent data on the use of specific MMP inhibitors in the treatment of several types of cancer.

Citing Articles

Causal effect of serum matrix metalloproteinase levels on venous thromboembolism: a Mendelian randomization study.

Han D, Yu F, Zheng L Epidemiol Health. 2024; 46:e2024046.

PMID: 38697862 PMC: 11417446. DOI: 10.4178/epih.e2024046.


MicroRNAs and proteolytic cleavage of receptors in cancers: A comprehensive review of regulatory interactions and therapeutic implications.

Hosseinpour-Soleimani F, Salmasi Z, Ghasemi Y, Tajbakhsh A, Savardashtaki A Heliyon. 2024; 10(7):e28167.

PMID: 38560206 PMC: 10979173. DOI: 10.1016/j.heliyon.2024.e28167.


Assessment of Selected Matrix Metalloproteinases (MMPs) and Correlation with Cytokines in Psoriatic Patients.

Michalak-Stoma A, Bartosinska J, Raczkiewicz D, Kowal M, Krasowska D, Chodorowska G Mediators Inflamm. 2021; 2021:9913798.

PMID: 34305455 PMC: 8263227. DOI: 10.1155/2021/9913798.


The Roles of Matrix Metalloproteinases and Their Inhibitors in Human Diseases.

Cabral-Pacheco G, Garza-Veloz I, Castruita-De la Rosa C, Ramirez-Acuna J, Perez-Romero B, Guerrero-Rodriguez J Int J Mol Sci. 2021; 21(24).

PMID: 33419373 PMC: 7767220. DOI: 10.3390/ijms21249739.


Destroy to Rebuild: The Connection Between Bone Tissue Remodeling and Matrix Metalloproteinases.

Hardy E, Fernandez-Patron C Front Physiol. 2020; 11:47.

PMID: 32116759 PMC: 7013034. DOI: 10.3389/fphys.2020.00047.